Skip to main content
StemCell Longevita
Flagship condition guide · Medical review required

Stem Cell Therapy for multiple sclerosis in Turkey – Istanbul

Written by
StemCell Longevita Editorial Team
Medically reviewed by
Professor of Histology and Embryology · Medical Director, Center for Regenerative Medicine
Last reviewed
Next scheduled review

How we evaluate evidence · Conflict-of-interest disclosure · Editorial standards

Clinical guide to MSC therapy for multiple sclerosis in Turkey, including MSC vs HSCT, evidence limits, candidacy, exclusions and Istanbul travel planning.

Can stem cell therapy help multiple sclerosis?

Mesenchymal stem cell therapy is not an approved treatment for multiple sclerosis and differs from autologous haematopoietic stem cell transplantation, which does have randomised evidence in aggressive relapsing disease. MSC trials report acceptable safety but inconsistent efficacy. Treatment here is offered alongside disease-modifying therapy, never as a replacement for it.

Key facts

Not the same as
AHSCT, which has randomised evidence in selected patients
MSC evidence
Safety acceptable, efficacy inconsistent
Standard care
Disease-modifying therapy continues

What we know

  • Randomised MSC trials in MS have reported safety but have not consistently met efficacy endpoints.

What remains uncertain

  • Which MS phenotype, if any, benefits from MSC administration.

Medically reviewed questions

For aggressive relapsing MS, discuss AHSCT with a neurologist — it has stronger randomised evidence, and it is a different, more intensive procedure.

No. Stopping disease-modifying therapy without neurology advice carries a real relapse risk.

This summary is general medical information, not medical advice, and not a promise of benefit. Figures are quoted ranges, confirmed in writing after a medical review.

Medically reviewed by: Prof. Dr. Erdal Karaöz · Last updated: · Editorial and evidence policy

Evidence at a glance — Multiple sclerosis

A plain summary of what the published research does and does not show for this condition. It is written to the same standard whether the evidence is strong or weak.

Human studies available?
Yes — including controlled studies
Randomised trials?
Randomised and sham-controlled trials completed (including MESEMS); no confirmed disease-modifying benefit
Main outcomes studied
  • Relapse rate
  • MRI lesion activity
  • EDSS disability
  • Safety
Long-term evidence
Limited
Regulatory approval for this indication
  • United States (FDA): No FDA-approved mesenchymal stem cell product for this indication. The FDA has issued consumer warnings about unapproved stem cell products.
  • European Union (EMA): No EMA-authorised mesenchymal stem cell medicine for this indication.
  • United Kingdom (MHRA): No MHRA-authorised mesenchymal stem cell medicine for this indication.
  • Türkiye (Ministry of Health): In Türkiye, cell therapies are delivered only inside Ministry of Health–licensed centres under the regenerative medicine / advanced therapy regulations, as clinical research or individual (exceptional) use — not as an approved routine treatment for this indication.
Role at our centre
Research context — considered only where standard care is exhausted or unsuitable, and never as a replacement for it

What kind of evidence exists

  • Mechanism (laboratory): Documented
  • Animal / preclinical: Documented
  • Early human (phase 1/2, uncontrolled): Documented
  • Controlled human (randomised or sham-controlled): Documented
  • Regulatory approval: Not established

Sources

Source links open filtered searches of PubMed and ClinicalTrials.gov plus regulator and professional-society pages, so you can read the current evidence yourself rather than a selected extract.

Evidence last reviewed: Next scheduled review: Medical reviewer: Prof. Dr. Erdal KaraözRead our editorial and evidence policy

This summary is general information about the evidence base, not medical advice and not a promise of benefit. Whether any treatment is appropriate for you can only be decided after a medical review of your records.

Medically reviewed by Prof. Dr. Erdal Karaöz
Share:

Records before recommendations

A proposed route is discussed only after diagnosis, investigations, current care and travel fitness have been reviewed.

No outcome guarantee

The evidence, uncertainty and reasons not to proceed are explained. Established care remains part of the decision.

Plan for continuity

Istanbul logistics, discharge documents and follow-up should connect with the clinician managing care at home.

What this page is for

A decision guide for patients comparing care

This page is for patients and families researching regenerative options for multiple sclerosis and comparing an Istanbul medical review with care available at home. It explains the evidence limits, questions that determine candidacy, reasons not to travel, protocol decisions, realistic expectations, costs and return-home follow-up.

Clinical decision guide

Before considering stem cell therapy for multiple sclerosis

The key question: Is the enquiry about immunoablation with HSCT, supportive MSC research or rehabilitation? The risk, evidence and candidacy are not interchangeable.

Evidence status

MSC and HSCT are different interventions. MSC approaches remain investigational for MS and should not be presented as a substitute for disease-modifying therapy.

Standard care first

An MS neurologist should review diagnosis, phenotype, disease activity, disease-modifying therapy and rehabilitation options before travel.

What the review checks

MS subtype, relapse and MRI activity, disability level, current DMT, infection risk, mobility, bladder function and recent steroid use.

When we redirect

Active infection, unstable disease, significant organ dysfunction or stopping effective DMT without the home neurologist's plan requires redirection.

Planning treatment in Istanbul

Account for heat sensitivity, fatigue, mobility, medication storage, thrombosis risk and transfer of records to the home MS team.

Continue your research

MS evidence guideCosts and travelRisks and exclusionsNeurological care pathway

How are stem cell and exosome approaches discussed for multiple sclerosis?

MSC research in multiple sclerosis explores immunomodulatory and tissue-support signalling. It is different from HSCT, which uses immunoablation and carries a substantially different risk profile. The two approaches must not be described as interchangeable.

Any regenerative discussion should start with MS phenotype, current disease activity and disease-modifying therapy. A proposed cell product should not displace effective neurological care or be promoted as rebuilding myelin.

Who may be considered?

Candidacy is never decided from age or diagnosis alone. A medical review looks for a clear clinical question, stable health, appropriate prior care and goals that can be followed after return home.

  • A confirmed MS phenotype with recent disease-activity information
  • Current disease-modifying therapy and infection risk reviewed by an MS clinician
  • Stable mobility and medical status compatible with travel

Who may not be suitable?

Active infection, unstable disease, significant organ dysfunction or stopping effective DMT without the home neurologist's plan requires redirection.

Active infection, unstable medical disease, pregnancy, active cancer treatment or inability to complete safe follow-up also require postponement, redirection or further specialist review.

How is a protocol for multiple sclerosis planned?

Route, dose, session count and stay length cannot be responsibly prescribed from a webpage. The written plan follows record review and should explain why each element is being proposed.

  1. 1

    Records and diagnosis review

    Recent specialist reports, investigations, medication and previous treatment are reviewed to confirm the clinical question and whether multiple sclerosis is stable enough for elective travel.

  2. 2

    Product and route discussion

    If an investigational option is discussed, the team should identify the cell or exosome product, source, testing, proposed route and why that route is being considered. No fixed dose or route is appropriate for every patient.

  3. 3

    Individual written plan

    Session count, timing, monitoring and supportive care are documented only after medical review. The plan should explain uncertainty, alternatives and what would cause treatment to be postponed or declined.

  4. 4

    Discharge and follow-up handover

    Patients receive product and procedure documentation, medication instructions, warning signs and a follow-up plan that can be shared with their clinician at home.

What results can realistically be expected?

The purpose of follow-up is to measure safety and agreed clinical goals—not to retrofit ordinary variation into a success claim.

  • There is no guaranteed response and no promise of cure, reversal, remission, tissue regrowth or stopping established medication.
  • Any goals should be condition-specific and measurable—for example function, symptoms, participation or rehabilitation tolerance—rather than a broad claim of regeneration.
  • The timing of any change is uncertain. Immediate post-procedure observations, later clinical review and longer-term follow-up serve different purposes; published research cannot predict an individual outcome.
  • No change, temporary symptoms or the need for further local assessment are possible outcomes and should be discussed before travel.

Why patients consider StemCell Longevita for multiple sclerosis

Patients may choose StemCell Longevita when they want an Istanbul review pathway built around records, written decisions and return-home coordination rather than a promise of results. These are the service standards to confirm during consultation:

Records are reviewed before a treatment recommendation or travel booking is requested

The medical team can explain why an enquiry may be declined or redirected

The proposed product, source, testing, route and traceability documents are identified in writing

Investigational options are distinguished from established treatment and medication is not stopped without the home clinician

The quotation separates clinical services, travel support, exclusions and potential extra costs

Discharge documents and a follow-up pathway are prepared for continuity with the home specialist

International patient journey for multiple sclerosis

Account for heat sensitivity, fatigue, mobility, medication storage, thrombosis risk and transfer of records to the home MS team.

  1. 1

    Private record review

    Send recent reports, imaging or test results and a current medication list. The team may request more information or advise against travel.

  2. 2

    Written planning before booking

    Confirm the proposed intervention, evidence status, exclusions, estimated stay, companion or accessibility needs, package inclusions and total quoted cost.

  3. 3

    Assessment in Istanbul

    Clinical review on arrival confirms that health status and records still support the plan. Treatment should be paused if new risks are identified.

  4. 4

    Discharge and return home

    Travel timing and support are adapted to multiple sclerosis. Warning signs, medication continuity and relevant documents are reviewed before departure.

  5. 5

    Remote follow-up

    Scheduled check-ins document safety and agreed outcomes, while the home specialist remains responsible for established disease management and urgent care.

How much does treatment for multiple sclerosis cost in Turkey?

A responsible quotation follows medical review. It should show the proposed clinical service and travel support separately enough for you to compare it with options in the UK, US, Germany or another home country.

  • Condition-page prices are not quoted before records are reviewed because product, route, session structure, monitoring and travel support can differ.
  • Ask for one written total showing the clinical service, laboratory or product documentation, hospital fees, tests, medication, transfers, accommodation and follow-up—and what is not included.
  • Comparisons with the UK, US, Germany or another home country should compare like-for-like private services, not imply that an investigational intervention is equivalent to licensed standard care.

Frequently asked questions about multiple sclerosis

MSC and HSCT are different interventions. MSC approaches remain investigational for MS and should not be presented as a substitute for disease-modifying therapy.

An MS neurologist should review diagnosis, phenotype, disease activity, disease-modifying therapy and rehabilitation options before travel.

MS subtype, relapse and MRI activity, disability level, current DMT, infection risk, mobility, bladder function and recent steroid use. Active infection, unstable disease, significant organ dysfunction or stopping effective DMT without the home neurologist's plan requires redirection.

Recent specialist reports, investigations, medication and previous treatment are reviewed to confirm the clinical question and whether multiple sclerosis is stable enough for elective travel. If an investigational option is discussed, the team should identify the cell or exosome product, source, testing, proposed route and why that route is being considered. No fixed dose or route is appropriate for every patient. Session count, timing, monitoring and supportive care are documented only after medical review. The plan should explain uncertainty, alternatives and what would cause treatment to be postponed or declined. Patients receive product and procedure documentation, medication instructions, warning signs and a follow-up plan that can be shared with their clinician at home.

There is no guaranteed response and no promise of cure, reversal, remission, tissue regrowth or stopping established medication. Any goals should be condition-specific and measurable—for example function, symptoms, participation or rehabilitation tolerance—rather than a broad claim of regeneration. The timing of any change is uncertain. Immediate post-procedure observations, later clinical review and longer-term follow-up serve different purposes; published research cannot predict an individual outcome. No change, temporary symptoms or the need for further local assessment are possible outcomes and should be discussed before travel.

Stay length is confirmed only after records, the proposed route, monitoring needs, mobility and companion requirements are reviewed. Patients should not book travel from a generic online timeline.

Condition-page prices are not quoted before records are reviewed because product, route, session structure, monitoring and travel support can differ. Ask for one written total showing the clinical service, laboratory or product documentation, hospital fees, tests, medication, transfers, accommodation and follow-up—and what is not included. Comparisons with the UK, US, Germany or another home country should compare like-for-like private services, not imply that an investigational intervention is equivalent to licensed standard care.

Records can be reviewed, but advanced disease does not automatically mean treatment is appropriate. Active infection, unstable disease, significant organ dysfunction or stopping effective DMT without the home neurologist's plan requires redirection. The review may recommend local specialist care or supportive planning instead of travel.

Start with a medical-record review

Send recent reports, investigations, medication lists and the questions you are discussing with your home specialist. Review may lead to a request for more information, a discussion of options, or advice not to travel.

Related clinical questions

Where this page sits in the wider picture.

Start here

Compare with

What the evidence says

Cost and next step

Related pages